Cancer Drug Shop BioVex Markets Legacy Technology for shRNA Delivery | GenomeWeb

By Doug Macron

Looking to eke out value from technology developed before a corporate restructuring, cancer drug developer BioVex has been marketing vectors, originally designed for drug delivery, for RNAi-based target validation applications.

The technology comprises replication-defective herpes simplex viruses that express shRNAs and can be delivered to the nervous system both in vitro and in vivo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.